O]ur companies have until June of 2028 to get there. That should not be a sigh of relief. That should be a, oh my gosh, we've got a lot of work," said Major.

The United States has long led the global biomedical research and pharmaceutical development industry - but that leadership ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor ...

Vir Biotechnology and Astellas entered a license agreement to co-develop and commercialize Vir's prostate cancer treatment. The agreement is for VIR-5500, a dual-masked T-cell engager targeting ...

Biotechnology has emerged as the fastest-growing segment, valued at $11.46 billion, led by fermentation-based industries, ...

Glass began as molten sand heated to 1700°C, yet it went on to power revolutions in science, medicine, warfare, and modern ...

Vir Biotechnology Inc is set to report fourth-quarter results today after the market close, with analysts expecting the clinical-stage biotech to post narrower losses as it advances its promising ...

A report said Karnataka’s bioeconomy touched USD 39.2 billion, underlining strong growth in biotechnology, research and life ...

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

The humble breadcrumb could hold the key to cutting out fossil fuels from one of the chemical industry's most widely used ...

Karnataka contributes 21 percent to India’s BioEconomy; adds 218 startups in 2025 as investments touch $1.14 billion ...

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...